257 related articles for article (PubMed ID: 28677529)
21. Generation of 'designer erythroblasts' lacking one or more blood group systems from CRISPR/Cas9 gene-edited human-induced pluripotent stem cells.
Pandey P; Zhang N; Curtis BR; Newman PJ; Denomme GA
J Cell Mol Med; 2021 Oct; 25(19):9340-9349. PubMed ID: 34547166
[TBL] [Abstract][Full Text] [Related]
22. Generation of a human induced pluripotent stem cell line with Cas9 driven by Tet-on operator via AAVS1 safe harbor gene-editing.
Ding Y; Wang L; Ji W; Chen Z; Wang D; Chen C; Tong H; Han Z; Niu C; Chu M; Huang J; Guo X
Stem Cell Res; 2020 Dec; 49():102064. PubMed ID: 33207306
[TBL] [Abstract][Full Text] [Related]
23. Efficient Gene Editing of Human Induced Pluripotent Stem Cells Using CRISPR/Cas9.
Yumlu S; Bashir S; Stumm J; Kühn R
Methods Mol Biol; 2019; 1961():137-151. PubMed ID: 30912045
[TBL] [Abstract][Full Text] [Related]
24. Human Induced Pluripotent Stem Cell NEUROG2 Dual Knockin Reporter Lines Generated by the CRISPR/Cas9 System.
Li S; Xue H; Wu J; Rao MS; Kim DH; Deng W; Liu Y
Stem Cells Dev; 2015 Dec; 24(24):2925-42. PubMed ID: 26414932
[TBL] [Abstract][Full Text] [Related]
25. Systematic gene tagging using CRISPR/Cas9 in human stem cells to illuminate cell organization.
Roberts B; Haupt A; Tucker A; Grancharova T; Arakaki J; Fuqua MA; Nelson A; Hookway C; Ludmann SA; Mueller IA; Yang R; Horwitz R; Rafelski SM; Gunawardane RN
Mol Biol Cell; 2017 Oct; 28(21):2854-2874. PubMed ID: 28814507
[TBL] [Abstract][Full Text] [Related]
26. Improved hematopoietic differentiation efficiency of gene-corrected beta-thalassemia induced pluripotent stem cells by CRISPR/Cas9 system.
Song B; Fan Y; He W; Zhu D; Niu X; Wang D; Ou Z; Luo M; Sun X
Stem Cells Dev; 2015 May; 24(9):1053-65. PubMed ID: 25517294
[TBL] [Abstract][Full Text] [Related]
27. Induced Pluripotent Stem Cells Meet Genome Editing.
Hockemeyer D; Jaenisch R
Cell Stem Cell; 2016 May; 18(5):573-86. PubMed ID: 27152442
[TBL] [Abstract][Full Text] [Related]
28. Transcription activator-like effector nuclease (TALEN)-mediated CLYBL targeting enables enhanced transgene expression and one-step generation of dual reporter human induced pluripotent stem cell (iPSC) and neural stem cell (NSC) lines.
Cerbini T; Funahashi R; Luo Y; Liu C; Park K; Rao M; Malik N; Zou J
PLoS One; 2015; 10(1):e0116032. PubMed ID: 25587899
[TBL] [Abstract][Full Text] [Related]
29. Advances in therapeutic CRISPR/Cas9 genome editing.
Savić N; Schwank G
Transl Res; 2016 Feb; 168():15-21. PubMed ID: 26470680
[TBL] [Abstract][Full Text] [Related]
30. Developing CRISPR/Cas9-Mediated Fluorescent Reporter Human Pluripotent Stem-Cell Lines for High-Content Screening.
Vojnits K; Nakanishi M; Porras D; Kim Y; Feng Z; Golubeva D; Bhatia M
Molecules; 2022 Apr; 27(8):. PubMed ID: 35458632
[TBL] [Abstract][Full Text] [Related]
31. Determining On-Target, Off-Target, and Copy Number Status of Transgenic Events After CRISPR/Cas9 Targeted AAVS1 Safe-Harbor Modification of iPSCs Using Double-Control Quantitative Copy Number PCR.
Schjeide BM; Püschel GP
Curr Protoc; 2023 Jan; 3(1):e635. PubMed ID: 36598341
[TBL] [Abstract][Full Text] [Related]
32. One-Step Generation of Seamless Luciferase Gene Knockin Using CRISPR/Cas9 Genome Editing in Human Pluripotent Stem Cells.
Li M; Hunt JFVS; Bhattacharyya A; Zhao X
Methods Mol Biol; 2019; 1942():61-69. PubMed ID: 30900175
[TBL] [Abstract][Full Text] [Related]
33. Generation of GFP Reporter Human Induced Pluripotent Stem Cells Using AAVS1 Safe Harbor Transcription Activator-Like Effector Nuclease.
Luo Y; Rao M; Zou J
Curr Protoc Stem Cell Biol; 2014 May; 29():5A.7.1-18. PubMed ID: 24838915
[TBL] [Abstract][Full Text] [Related]
34. One-step genetic correction of hemoglobin E/beta-thalassemia patient-derived iPSCs by the CRISPR/Cas9 system.
Wattanapanitch M; Damkham N; Potirat P; Trakarnsanga K; Janan M; U-Pratya Y; Kheolamai P; Klincumhom N; Issaragrisil S
Stem Cell Res Ther; 2018 Feb; 9(1):46. PubMed ID: 29482624
[TBL] [Abstract][Full Text] [Related]
35. Efficient gene editing in induced pluripotent stem cells enabled by an inducible adenine base editor with tunable expression.
Nandy K; Babu D; Rani S; Joshi G; Ijee S; George A; Palani D; Premkumar C; Rajesh P; Vijayanand S; David E; Murugesan M; Velayudhan SR
Sci Rep; 2023 Dec; 13(1):21953. PubMed ID: 38081875
[TBL] [Abstract][Full Text] [Related]
36. Application of CRISPR/Cas9 to the study of brain development and neuropsychiatric disease.
Powell SK; Gregory J; Akbarian S; Brennand KJ
Mol Cell Neurosci; 2017 Jul; 82():157-166. PubMed ID: 28549865
[TBL] [Abstract][Full Text] [Related]
37. Production of genome-edited pluripotent stem cells and mice by CRISPR/Cas.
Horii T; Hatada I
Endocr J; 2016; 63(3):213-9. PubMed ID: 26743444
[TBL] [Abstract][Full Text] [Related]
38. Genome Editing in Induced Pluripotent Stem Cells using CRISPR/Cas9.
Ben Jehuda R; Shemer Y; Binah O
Stem Cell Rev Rep; 2018 Jun; 14(3):323-336. PubMed ID: 29623532
[TBL] [Abstract][Full Text] [Related]
39. Reversal of Phenotypic Abnormalities by CRISPR/Cas9-Mediated Gene Correction in Huntington Disease Patient-Derived Induced Pluripotent Stem Cells.
Xu X; Tay Y; Sim B; Yoon SI; Huang Y; Ooi J; Utami KH; Ziaei A; Ng B; Radulescu C; Low D; Ng AYJ; Loh M; Venkatesh B; Ginhoux F; Augustine GJ; Pouladi MA
Stem Cell Reports; 2017 Mar; 8(3):619-633. PubMed ID: 28238795
[TBL] [Abstract][Full Text] [Related]
40. Generation of heterozygous (MRli003-A-5) and homozygous (MRli003-A-6) voltage-sensing knock-in human iPSC lines by CRISPR/Cas9 editing of the AAVS1 locus.
Zhang F; Meier AB; Sinnecker D; Engelhardt S; Lipp P; Laugwitz KL; Dorn T; Moretti A
Stem Cell Res; 2022 May; 61():102785. PubMed ID: 35421847
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
